The author established synthetic protocols for two protein domains derived from the T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) and human serum albumin (HSA). Additionally, the author developed a synthetic variant of mirror-image monobody, an artificial protein scaffold for specific target binding. These protein domains are valuable tools for developing less-immunogenic protein therapeutics.